1064 related articles for article (PubMed ID: 31805946)
1. Harnessing tumor-associated macrophages as aids for cancer immunotherapy.
Li X; Liu R; Su X; Pan Y; Han X; Shao C; Shi Y
Mol Cancer; 2019 Dec; 18(1):177. PubMed ID: 31805946
[TBL] [Abstract][Full Text] [Related]
2. Macrophage targeting in cancer.
Lopez-Yrigoyen M; Cassetta L; Pollard JW
Ann N Y Acad Sci; 2021 Sep; 1499(1):18-41. PubMed ID: 32445205
[TBL] [Abstract][Full Text] [Related]
3. Targeting tumor-associated macrophages as an antitumor strategy.
Cheng N; Bai X; Shu Y; Ahmad O; Shen P
Biochem Pharmacol; 2021 Jan; 183():114354. PubMed ID: 33279498
[TBL] [Abstract][Full Text] [Related]
4. Current Strategies to Target Tumor-Associated-Macrophages to Improve Anti-Tumor Immune Responses.
Anfray C; Ummarino A; Andón FT; Allavena P
Cells; 2019 Dec; 9(1):. PubMed ID: 31878087
[No Abstract] [Full Text] [Related]
5. New Mechanisms of Tumor-Associated Macrophages on Promoting Tumor Progression: Recent Research Advances and Potential Targets for Tumor Immunotherapy.
Guo Q; Jin Z; Yuan Y; Liu R; Xu T; Wei H; Xu X; He S; Chen S; Shi Z; Hou W; Hua B
J Immunol Res; 2016; 2016():9720912. PubMed ID: 27975071
[TBL] [Abstract][Full Text] [Related]
6. The interaction of anticancer therapies with tumor-associated macrophages.
Mantovani A; Allavena P
J Exp Med; 2015 Apr; 212(4):435-45. PubMed ID: 25753580
[TBL] [Abstract][Full Text] [Related]
7. Tumor-associated macrophages: A promising target for a cancer immunotherapeutic strategy.
Zhang SY; Song XY; Li Y; Ye LL; Zhou Q; Yang WB
Pharmacol Res; 2020 Nov; 161():105111. PubMed ID: 33065284
[TBL] [Abstract][Full Text] [Related]
8. Targeting tumor-associated macrophages: A potential treatment for solid tumors.
Chen Y; Jin H; Song Y; Huang T; Cao J; Tang Q; Zou Z
J Cell Physiol; 2021 May; 236(5):3445-3465. PubMed ID: 33200401
[TBL] [Abstract][Full Text] [Related]
9. Re-education of macrophages as a therapeutic strategy in cancer.
Kowal J; Kornete M; Joyce JA
Immunotherapy; 2019 Jun; 11(8):677-689. PubMed ID: 31088236
[TBL] [Abstract][Full Text] [Related]
10. Tumor-associated macrophages: role in cancer development and therapeutic implications.
Salmaninejad A; Valilou SF; Soltani A; Ahmadi S; Abarghan YJ; Rosengren RJ; Sahebkar A
Cell Oncol (Dordr); 2019 Oct; 42(5):591-608. PubMed ID: 31144271
[TBL] [Abstract][Full Text] [Related]
11. Macrophages in the microenvironment of head and neck cancer: potential targets for cancer therapy.
Evrard D; Szturz P; Tijeras-Raballand A; Astorgues-Xerri L; Abitbol C; Paradis V; Raymond E; Albert S; Barry B; Faivre S
Oral Oncol; 2019 Jan; 88():29-38. PubMed ID: 30616794
[TBL] [Abstract][Full Text] [Related]
12. Redirecting tumor-associated macrophages to become tumoricidal effectors as a novel strategy for cancer therapy.
Zheng X; Turkowski K; Mora J; Brüne B; Seeger W; Weigert A; Savai R
Oncotarget; 2017 Jul; 8(29):48436-48452. PubMed ID: 28467800
[TBL] [Abstract][Full Text] [Related]
13. Targeting tumor associated macrophages (TAMs) via nanocarriers.
Singh Y; Pawar VK; Meher JG; Raval K; Kumar A; Shrivastava R; Bhadauria S; Chourasia MK
J Control Release; 2017 May; 254():92-106. PubMed ID: 28377038
[TBL] [Abstract][Full Text] [Related]
14. Re-education of the Tumor Microenvironment With Targeted Therapies and Immunotherapies.
Ngiow SF; Young A
Front Immunol; 2020; 11():1633. PubMed ID: 32849557
[TBL] [Abstract][Full Text] [Related]
15. Blockade of DC-SIGN
Hu B; Wang Z; Zeng H; Qi Y; Chen Y; Wang T; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Liu L; Zhu Y; Dai B; Guo J; Xu L; Zhang W; Xu J
Cancer Res; 2020 Apr; 80(8):1707-1719. PubMed ID: 32060149
[TBL] [Abstract][Full Text] [Related]
16. Progress in tumor-associated macrophage (TAM)-targeted therapeutics.
Ngambenjawong C; Gustafson HH; Pun SH
Adv Drug Deliv Rev; 2017 May; 114():206-221. PubMed ID: 28449873
[TBL] [Abstract][Full Text] [Related]
17. Molecular Repolarisation of Tumour-Associated Macrophages.
van Dalen FJ; van Stevendaal MHME; Fennemann FL; Verdoes M; Ilina O
Molecules; 2018 Dec; 24(1):. PubMed ID: 30577495
[TBL] [Abstract][Full Text] [Related]
18. M1 Macrophage-Derived Nanovesicles Potentiate the Anticancer Efficacy of Immune Checkpoint Inhibitors.
Choo YW; Kang M; Kim HY; Han J; Kang S; Lee JR; Jeong GJ; Kwon SP; Song SY; Go S; Jung M; Hong J; Kim BS
ACS Nano; 2018 Sep; 12(9):8977-8993. PubMed ID: 30133260
[TBL] [Abstract][Full Text] [Related]
19. Diamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer Therapy.
Clappaert EJ; Murgaski A; Van Damme H; Kiss M; Laoui D
Front Immunol; 2018; 9():2250. PubMed ID: 30349530
[TBL] [Abstract][Full Text] [Related]
20. Activation of phagocytosis by immune checkpoint blockade.
Li CW; Lai YJ; Hsu JL; Hung MC
Front Med; 2018 Aug; 12(4):473-480. PubMed ID: 30062558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
